Skip to main content

Vivos Therapeutics, Inc.

corporate_fare Company Profile

Vivos Therapeutics, Inc.

VVOS·NASDAQ·Industrial Applications And Services·CIK 0001716166

Vivos Therapeutics, Inc. is a revenue stage medical technology and healthcare services company that provides a comprehensive suite of proprietary oral appliances and therapeutic treatments. The company's products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws linked to breathing and sleep disorders, including mild to severe obstructive sleep apnea (OSA) and snoring in adults. This approach, called The Vivos Method, combines the use of their appliances with specific therapeutic treatment protocols. The Vivos Method is estimated to be indicated and potentially effective in approximately 80% of OSA cases where patients comply with clinical treatments, within the scope of FDA cleared uses. Vivos's patented C.A.R.E. oral appliances have been used by approximately 60,000 patients treated worldwide by over 2,000 trained dentists. Their other lines of oral appliances have treated an estimated additional 15,000 or more patients globally. Since 2024, the company has been shifting its business model to generate revenue from appliance sales and the provision of healthcare services. This involves acquiring and managing sleep medical practices that diagnose and treat OSA, and establishing Vivos-supported and managed Dental and Medical Service Organizations (DSOs and MSOs). The company has started branding its OSA treatment business as Sleep and Airway Medicine Centers (SAMC). The Vivos Method now includes a broader range of product and service lines beyond the proprietary technologies in their C.A.R.E. appliances.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 48 items for VVOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 13 rated 8 or above. Recent SEC coverage for VVOS spans DEF 14A, PRER14A, PRE 14A, 8-K.

Recent high-impact activity:

  • Vivos Proxy Sets Dec 2 Vote on 1-for-20 to 1-for-40 Reverse Split and Massive Preferred Conversions
  • Vivos Proxy Seeks Approval for ~98M Potential New Shares, Reverse Split and Nevada Move
  • Vivos Closes No-Cash SOD Deal, Claims $10M+ Equity Boost and Nasdaq Cure
  • Vivos Proxy Seeks Approval for 1-for-20 to 1-for-40 Reverse Split and Up to 98M Dilutive Shares
  • Vivos Closes SOD Deal, Claims Nasdaq Equity Compliance on $10.4M Booked Gain

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$17.44M
Net Income
-$21.17M
Diluted EPS
-$2.07
Op. Cash Flow
-$15.26M
Free Cash Flow
-$17.6M
Gross Profit
$10.54M
Operating Income
-$19.89M
Cash & Equivalents
$2.03M
Total Debt
$8.82M
Debt / Equity
-5.92×
Net Margin
-121.4%
Shares Outstanding
9.29M sh
Source: 10-K · filed 2026-04-15 · accession 0001493152-26-016854

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 2,358,382 shares in VVOS as of the October 15, 2026 settlement, a 17.7% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 26.0% of VVOS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,358,382 shares as of October 15, 2026
Change vs prior period▼ 17.7%
Days to cover1.00 at avg daily volume of 2,426,297
Daily short volume (FINRA facilities)26.0% of 427,111 shares on October 30, 2026
5-day average short volume25.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for VVOS, detected from its recent SEC filings · based on capital-structure filings through 2026-09-04.

Debt-for-Equity Exchange with Streeterville · Massive Dilution to Existing Holders

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$0.1145 +0.62% today
52-week range · as of 2026-10-29 $0.1145 – $2.88
Market cap
$3.82M
Volume
741.9K (0.1× avg)
3-mo avg 8.4M
Live data · 2026-11-01 02:32 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VVOS - Latest Insights

VVOS
Oct 29, 2026, 3:55 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.12085
Real-time Price: $0.1145 info
Change: -$0.00635 (-5%) info
Market Cap: $3.825M info
VVOS
Oct 21, 2026, 4:15 PM EDT
Filing Type: PRER14A
Importance Score:
8
Price at Filing: $0.1323
Real-time Price: $0.1145 info
Change: -$0.0178 (-13%) info
Market Cap: $3.825M info
VVOS
Oct 19, 2026, 5:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1579
Real-time Price: $0.1145 info
Change: -$0.0434 (-27%) info
Market Cap: $3.825M info
VVOS
Oct 19, 2026, 4:58 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.1476
Real-time Price: $0.1145 info
Change: -$0.0331 (-22%) info
Market Cap: $3.825M info
VVOS
Oct 19, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1339
Real-time Price: $0.1145 info
Change: -$0.0194 (-14%) info
Market Cap: $3.825M info
VVOS
Oct 15, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1357
Real-time Price: $0.1145 info
Change: -$0.0212 (-16%) info
Market Cap: $3.825M info
VVOS
Oct 15, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1559
Real-time Price: $0.1145 info
Change: -$0.0414 (-27%) info
Market Cap: $3.825M info
VVOS
Oct 01, 2026, 6:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.1451
Real-time Price: $0.1145 info
Change: -$0.0306 (-21%) info
Market Cap: $3.825M info
VVOS
Sep 30, 2026, 9:54 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1451
Real-time Price: $0.1145 info
Change: -$0.0306 (-21%) info
Market Cap: $3.825M info
VVOS
Sep 29, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1545
Real-time Price: $0.1145 info
Change: -$0.040 (-26%) info
Market Cap: $3.825M info
VVOS
Sep 04, 2026, 6:26 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.174
Real-time Price: $0.1145 info
Change: -$0.0595 (-34%) info
Market Cap: $3.825M info
VVOS
Aug 28, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.2593
Real-time Price: $0.1145 info
Change: -$0.1448 (-56%) info
Market Cap: $3.825M info
VVOS
Aug 25, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.2801
Real-time Price: $0.1145 info
Change: -$0.1656 (-59%) info
Market Cap: $3.825M info
VVOS
Aug 14, 2026, 4:28 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3432
Real-time Price: $0.1145 info
Change: -$0.2287 (-67%) info
Market Cap: $3.825M info
VVOS
Aug 14, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.340
Real-time Price: $0.1145 info
Change: -$0.2255 (-66%) info
Market Cap: $3.825M info
VVOS
Aug 11, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3222
Real-time Price: $0.1145 info
Change: -$0.2077 (-64%) info
Market Cap: $3.825M info
VVOS
Aug 03, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4254
Real-time Price: $0.1145 info
Change: -$0.3109 (-73%) info
Market Cap: $3.825M info
VVOS
Jul 15, 2026, 5:07 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $0.420
Real-time Price: $0.1145 info
Change: -$0.3055 (-73%) info
Market Cap: $3.825M info
VVOS
Jul 15, 2026, 4:23 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4129
Real-time Price: $0.1145 info
Change: -$0.2984 (-72%) info
Market Cap: $3.825M info
VVOS
Jul 07, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.479
Real-time Price: $0.1145 info
Change: -$0.3645 (-76%) info
Market Cap: $3.825M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets